Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: Is there hope?

Thomas A. Schmidt^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Leder › Forskning › peer review

Originalsprog	Engelsk
Sider (fra-til)	4-5
Antal sider	2
Tidsskrift	European Heart Journal - Cardiovascular Pharmacotherapy
Vol/bind	4
Udgave nummer	1
DOI	https://doi.org/10.1093/ehjcvp/pvx026
Status	Udgivet - 1 jan. 2018

Adgang til dokumentet

@article{59244f5fa1c24ae2bd7087a54b5a867e,

title = "Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: Is there hope?",

author = "Schmidt, {Thomas A.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1093/ehjcvp/pvx026",

language = "English",

volume = "4",

pages = "4--5",

journal = "European Heart Journal - Cardiovascular Pharmacotherapy",

issn = "2055-6837",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes

T2 - Is there hope?

AU - Schmidt, Thomas A.

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85047053503&partnerID=8YFLogxK

U2 - 10.1093/ehjcvp/pvx026

DO - 10.1093/ehjcvp/pvx026

M3 - Editorial

C2 - 29315396

AN - SCOPUS:85047053503

VL - 4

SP - 4

EP - 5

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 1

ER -